Speciality Medicines Limited (BOM:544738)
India · Delayed Price · Currency is INR 151.20
-6.05 (-3.85%)
At close: Aug 21, 2026
Speciality Medicines Revenue
In the fiscal year ending March 31, 2026, Speciality Medicines had annual revenue of 752.85M INR with 29.20% growth.
Revenue
752.85M
Revenue Growth
+29.20%
P/S Ratio
1.76
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.33B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 752.85M | 170.14M | 29.20% |
| Mar 31, 2025 | 582.71M | 307.47M | 111.71% |
| Mar 31, 2024 | 275.25M | 42.84M | 18.43% |
| Mar 31, 2023 | 232.41M | -172.03M | -42.54% |
| Mar 31, 2022 | 404.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bal Pharma | 3.34B |
| Parnax Lab | 2.52B |
| Sat Kartar Life | 2.01B |
| Lactose (India) | 1.71B |
| Aayush Wellness | 1.66B |
| Makers Laboratories | 1.49B |
| Concord Drugs | 860.69M |
| Mercury Laboratories | 737.65M |